Stoke Therapeutics (STOK) - Stock Price & Dividends

Stoke Therapeutics, Inc. (NASDAQ: STOK) is a biopharmaceutical company in the United States that focuses on developing medications to address severe genetic conditions. They employ a unique method called targeted augmentation of nuclear gene output to create antisense oligonucleotides that can rebalance protein levels affected by genetic diseases.

Their main experimental drug, STK-002, is currently in the preclinical phase and targets autosomal dominant optic atrophy. Additionally, Stoke Therapeutics is working on STK-001, in the phase I/II clinical trial stage, intended for the treatment of Dravet syndrome. They are also involved in developing therapies for haploinsufficiency ailments affecting the nervous system and eyes.

In pursuit of cutting-edge solutions, Stoke Therapeutics has formed a partnership with Acadia Pharmaceuticals Inc. to collaborate on the creation of innovative RNA-based medicines to tackle severe and rare genetic neurodevelopmental disorders of the central nervous system.

Established in 2014 and previously known as ASOthera Pharmaceuticals, the company rebranded as Stoke Therapeutics, Inc. in 2016. Headquartered in Bedford, Massachusetts, Stoke Therapeutics is committed to advancing medical care for individuals grappling with genetic ailments. To learn more, visit their website at https://www.stoketherapeutics.com.